CHARLES WYKOFF to History, 18th Century
This is a "connection" page, showing publications CHARLES WYKOFF has written about History, 18th Century.
Connection Strength
0.112
-
SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results. Ophthalmic Surg Lasers Imaging Retina. 2013 Mar-Apr; 44(2):121-6.
Score: 0.112